Boston Scientific Corp. announced it has closed an investment and entered into an acquisition option agreement with Millipede Inc., a privately-held company that has developed the IRIS Transcatheter Annuloplasty Ring System for the treatment of severe mitral regurgitation (MR). Under the terms of the agreements, Boston Scientific has purchased a portion of the outstanding shares of Millipede along with newly issued shares of the company for a total consideration of $90M. Boston Scientific has the option to acquire the remaining shares of the company at any time prior to the completion of a first in human clinical study that meets certain parameters. Upon the completion of the clinical study, Millipede has the option to compel Boston Scientific to acquire the remaining shares of the company. Each company's option period expires by the end of 2019. Completion of this acquisition would result in an additional $325M payment by Boston Scientific at closing with a further $125M becoming payable upon achievement of a commercial milestone.

Clear detail of the in-stent restenosis can be seen in this image from the new high-resolution Canon Precision CT system. RSNA 2017, #RSNA2017, #RSNA17
Samsung's new carotid vascular analysis package used an automated 3-D recontruction of the vessel and plaque burden to more accurately assess cardiovascular and stroke risk. RSNA 2017, #RSNA2017, #RSNA17
Example of Novarad's augmented reality for surgical planning and guidance. RSNA 2017, #RSNA2017, #RSNA17
The view through a HoloLens headset in the Philips RSNA 2017 booth of holographic reconstruction of liver anatomy to guide a liver tumor embolization procedure. The augmented reality 3-D reconstruction can be rotated by hand movement or voice commands. RSNA 2017, #RSNA2017, #RSNA17
Siemens unveiled its new Nexaris therapy platform, which combines the vendor’s robotic angiography Artis pheno system with either an in-room CT system, or allows pairing with a Siemens MRI scanner. RSNA 2017, #RSNA2017, #RSNA17
An RSNA attendee using Novarad’s OpenSight augmented reality for surgical applications. RSNA 2017, #RSNA2017, #RSNA17
Stratasys introduced its Biomimics product. It combines several existing 3-D printing materials with new software that allows users to create custom, life-like anatomy that mimics the physical traits of actual tissues. RSNA 2017, #RSNA2017, #RSNA17
RSNA 2017, #RSNA2017, #RSNA17
GE Healthcare rolled out its first implementation of AI in its ultrasound systems, starting with its new point-of-care Venue system. RSNA 2017, #RSNA2017, #RSNA17
GE Healthcare showed a new Assist technology for its interventional guided therapy (IGS) angiography systems' rotational angiography. RSNA 2017, #RSNA2017, #RSNA17

Medical imaging plays a key role in cardiology, and most of the newest radiology technology advances are first unveiled at the world’s largest radiology conference, the Radiological Society of North America (RSNA) meeting held each November in Chicago. RSNA 2017 included several key technology advances in several modalities that will impact cardiovascular imaging and will likely be discussed or shown at the key cardiology meetings in 2018. 

January 23, 2018 – Imricor Medical Systems announced the completion of enrollment for the clinical study to evaluate Imricor’s Vision-MR Ablation Catheter for the treatment of atrial flutter under real-time magnetic resonance imaging (MRI) guidance. The single-center study enrolled 35 patients and was sponsored by the University of Leipzig Heart Center in Leipzig, Germany.

January 23, 2018 – Siemens Healthineers and Florida Hospital, part of Adventist Health System, have announced a multi-phase collaboration agreement for the development of several outcomes-based collaborative projects. The long-term agreement leverages the imaging technology innovation and industry expertise of Siemens Healthineers as well as the integrated delivery network (IDN) of Florida Hospital and its ongoing investment in improving healthcare affordability, outcomes and experience for their customers.

Here is a list of the American College of Cardiology (ACC) 2018 annual meeting late-breaking clinical trials presented at ACC18, March 10-12 in Orlando, Fla. The studies are linked to articles specific to the trial presentations.

Preview some of the hot topics at at ACC 2018 with the editor's of the ACC journals in the article "What Trends are Ahead in Cardiovascular Medicine in 2018?"
 

 

January 23, 2017 – At the annual meeting of Radiological Society of North America, 3D Systems announced a new D2P (DICOM to PRINT) technology that helps clinicians and radiologists quickly create accurate, digital 3-D anatomical models from medical imaging data.

Industry-First Volume Virtual Reality Software

The bioresorbable Cordis Mynx Grip vascular closure device seals arteriotomies without use of permanent hardware.
Marine Polymer Technologies’s SyvekRadial Radial compression band to achieve radial access hemostatsis, vascular closure.

While manual compression remains the gold standard for hemostasis of catheterization vascular access site arteriotomies, the current cost-conscious era of making healthcare more cost-effective has renewed interest in technologies to speed vascular closure. 

The U.S. Food and Drug Administration (FDA) announced last week it is providing information and recommendations regarding the Zoll LifeVest 4000 due to concerns that the device may fail to deliver treatment to the patient if the device is not replaced soon after displaying "Call for service: Device has a problem that may require service. Call Zoll for service, Message Code 102." Failure to contact Zoll and immediately replace the device after Message Code 102 appears on the device screen may result in serious patient harm or death of the patient because the device may fail to deliver therapy appropriately when needed.

January 22, 2018 — Baxter International Inc. announced the U.S. Food and Drug Administration (FDA) approval of Bivalirudin in 0.9 percent Sodium Chloride Injection (bivalirudin). Bivalirudin is a specific and direct thrombin inhibitor indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI), a common non-surgical procedure to treat blocked or narrowed blood vessels in the heart.

Ligand Pharmaceuticals Inc. announced initiation of a program to develop contrast agents with reduced renal toxicity. Through this new, internally-funded program, Ligand intends to advance products toward proof-of-concept, followed by selling or out-licensing them for further development and commercialization. The program will leverage Ligand’s patented Captisol technology, as well as data and intellectual property obtained through its acquisition of Verrow Pharmaceuticals, a privately-held Lenexa, Kansas-based medical invention company that Ligand acquired in January 2018 for $2 million in cash plus earnouts.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now